Centre for Prions and Protein Folding Diseases, University of Alberta, Edmonton, Alberta, Canada, T6G 2M8.
Mol Neurobiol. 2013 Feb;47(1):37-63. doi: 10.1007/s12035-012-8337-y. Epub 2012 Sep 16.
Alzheimer's disease (AD) is a complex multifactorial neurodegenerative disorder believed to be initiated by accumulation of amyloid β (Aβ)-related peptides derived from proteolytic processing of amyloid precursor protein (APP). Research over the past two decades provided a mechanistic link between cholesterol and AD pathogenesis. Genetic polymorphisms in genes regulating the pivotal points in cholesterol metabolism have been suggested to enhance the risk of developing AD. Altered neuronal membrane cholesterol level and/or subcellular distribution have been implicated in aberrant formation, aggregation, toxicity, and degradation of Aβ-related peptides. However, the results are somewhat contradictory and we still do not have a complete understanding on how cholesterol can influence AD pathogenesis. In this review, we summarize our current understanding on the role of cholesterol in regulating the production/function of Aβ-related peptides and also examine the therapeutic potential of regulating cholesterol homeostasis in the treatment of AD pathology.
阿尔茨海默病(AD)是一种复杂的多因素神经退行性疾病,据信是由淀粉样β(Aβ)相关肽的积累引发的,这些肽源自淀粉样前体蛋白(APP)的蛋白水解处理。过去二十年的研究为胆固醇与 AD 发病机制之间提供了一个机制联系。据推测,调节胆固醇代谢关键要点的基因中的遗传多态性会增加患 AD 的风险。改变神经元膜胆固醇水平和/或亚细胞分布与 Aβ相关肽的异常形成、聚集、毒性和降解有关。然而,结果有些矛盾,我们仍然不完全了解胆固醇如何影响 AD 的发病机制。在这篇综述中,我们总结了我们目前对胆固醇在调节 Aβ相关肽的产生/功能中的作用的理解,同时也研究了调节胆固醇动态平衡在治疗 AD 病理中的治疗潜力。